2022
2021
2020
2019
2018
2017
2016
2015
2014
←
1
2
Tenax Therapeutics Announces New Scientific Publication of Preclinical Data Provides Additional Evidence of Levosimendan Treatment Effects in Pulmonary Hypertension
Mar 1, 2018
Tenax Therapeutics Announces Reverse Stock Split
Feb 23, 2018
World-Recognized Experts Join Tenax Therapeutics’ Scientific Advisory Board to Guide New Phase 2 Study
Feb 6, 2018
Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
Jan 16, 2018